Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Of particular note to investors, the data presented here best represents investor expectations and data derived from company presentations and may not necessarily be accurate.
Opexa Therapeutics
Opexa Therapeutics Inc (NASDAQ: OPXA) is a biopharmaceutical company focused on the treatment of various diseases, including multiple sclerosis. The company indicated in a presentation that top-line data from a Phase 2b study involving its tovaxin (Tcelna) could be reported on October 14.
Egalet
Egalet Corp (NASDAQ: EGLT) is a specialty pharmaceutical company that manufacturers and commercializes treatments for pain and other conditions.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
A U.S. Food and Drug Administration (FDA) advisory committee voted 18 to 1 to recommend approval for the company's ARYMP ER (morphine sulfate) for the treatment of pain severe enough to require daily long-term opiod treatment.
The FDA is not bound by the recommendation of the advisory committee but will consider their guidance during a review. The FDA Prescription Drug User Fee Act (PDFUA) goal date for a decision is scheduled for October 14.
Windtree Therapeutics
Windtree Therapeutics Inc (NASDAQ: WINT) is a biotechnology company focused on developing therapies for respiratory diseases and other potential applications.
The company said in an SEC regulatory filing that enrollment in an AEROSURF phase 2a clinical study involving 32 premature infants receiving the company's proprietary KL4 surfactant with its novel aerosol delivery system.
Enrollment was expected to be completed in September 2016, and top-line results were said to be released "in late September or early October 2016."
At Last Check ...
- iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) was down 0.14 percent at $269.76.
- Egalet was down 1.21 percent at $7.32.
- Opexa was down 5.15 percent at $3.68.
- Windtree was down 1.66 percent at $2.66.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.